Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia’s proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.
Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders
August 25, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022